Literature DB >> 20335268

Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.

Ying Dang1, Roderick W Davis, Ian A York, Yong-Hui Zheng.   

Abstract

The human cytidine deaminases APOBEC3G (A3G) and APOBEC3F (A3F) potently restrict human immunodeficiency virus type 1 (HIV-1) replication, but they are neutralized by the viral protein Vif. Vif bridges A3G and A3F with a Cullin 5 (Cul5)-based E3 ubiquitin ligase and mediates their proteasomal degradation. This mechanism has been extensively studied, and several Vif domains have been identified that are critical for A3G and A3F neutralization. Here, we identified two additional domains. Via sequence analysis of more than 2,000 different HIV-1 Vif proteins, we identified two highly conserved amino acid sequences, (81)LGxGxSIEW(89) and (171)EDRWN(175). Within the (81)LGxGxSIEW(89) sequence, residues L81, G82, G84, and, to a lesser extent, I87 and W89 play very critical roles in A3G/A3F neutralization. In particular, residues L81 and G82 determine Vif binding to A3F, residue G84 determines Vif binding to both A3G and A3F, and residues (86)SIEW(89) affect Vif binding to A3F, A3G, and Cul5. Accordingly, this (81)LGxGxSIEW(89) sequence was designated the (81)LGxGxxIxW(89) domain. Within the (171)EDRWN(175) sequence, all residues except N175 are almost equally important for regulation of A3F neutralization, and consistently, they determine Vif binding only to A3F. Accordingly, this domain was designated (171)EDRW(174). The LGxGxxIxW domain is also partially conserved in simian immunodeficiency virus Vif from rhesus macaques (SIVmac239) and has a similar activity. Thus, (81)LGxGxxIxW(89) and (171)EDRW(174) are two novel functional domains that are very critical for Vif function. They could become new targets for inhibition of Vif activity during HIV replication.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20335268      PMCID: PMC2876610          DOI: 10.1128/JVI.00079-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  A zinc-binding region in Vif binds Cul5 and determines cullin selection.

Authors:  Andrew Mehle; Elaine R Thomas; Kottampatty S Rajendran; Dana Gabuzda
Journal:  J Biol Chem       Date:  2006-04-24       Impact factor: 5.157

2.  Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.

Authors:  Andrew Mehle; Joao Goncalves; Mariana Santa-Marta; Mark McPike; Dana Gabuzda
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

3.  Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G.

Authors:  Kun Luo; Zuoxiang Xiao; Elana Ehrlich; Yunkai Yu; Bindong Liu; Shu Zheng; Xiao-Fang Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-02       Impact factor: 11.205

4.  HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.

Authors:  Mariana Santa-Marta; Frederico Aires da Silva; Ana Margarida Fonseca; Joao Goncalves
Journal:  J Biol Chem       Date:  2004-12-20       Impact factor: 5.157

5.  Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif.

Authors:  Zuoxiang Xiao; Elana Ehrlich; Yunkai Yu; Kun Luo; Tao Wang; Chunjuan Tian; Xiao-Fang Yu
Journal:  Virology       Date:  2006-03-13       Impact factor: 3.616

Review 6.  Host restriction of HIV-1 by APOBEC3 and viral evasion through Vif.

Authors:  Anna Maria Niewiadomska; Xiao-Fang Yu
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

7.  Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.

Authors:  Bärbel Schröfelbauer; Tilo Senger; Gerard Manning; Nathaniel R Landau
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

8.  Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif.

Authors:  Brian P Doehle; Alexandra Schäfer; Bryan R Cullen
Journal:  Virology       Date:  2005-09-01       Impact factor: 3.616

9.  Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H.

Authors:  Molly OhAinle; Julie A Kerns; Harmit S Malik; Michael Emerman
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells.

Authors:  Sandra Kao; Eri Miyagi; Mohammad A Khan; Hiroaki Takeuchi; Sandrine Opi; Ritu Goila-Gaur; Klaus Strebel
Journal:  Retrovirology       Date:  2004-09-17       Impact factor: 4.602

View more
  37 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  Identification of a Cullin5-ElonginB-ElonginC E3 complex in degradation of feline immunodeficiency virus Vif-mediated feline APOBEC3 proteins.

Authors:  Jiawen Wang; Wenyan Zhang; Mingyu Lv; Tao Zuo; Wei Kong; Xianghui Yu
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

3.  Structural Insights into HIV-1 Vif-APOBEC3F Interaction.

Authors:  Masaaki Nakashima; Hirotaka Ode; Takashi Kawamura; Shingo Kitamura; Yuriko Naganawa; Hiroaki Awazu; Shinya Tsuzuki; Kazuhiro Matsuoka; Michiko Nemoto; Atsuko Hachiya; Wataru Sugiura; Yoshiyuki Yokomaku; Nobuhisa Watanabe; Yasumasa Iwatani
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

4.  Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.

Authors:  Erez Pery; Ann Sheehy; N Miranda Nebane; Andrew Jay Brazier; Vikas Misra; Kottampatty S Rajendran; Sara J Buhrlage; Marie K Mankowski; Lynn Rasmussen; E Lucile White; Roger G Ptak; Dana Gabuzda
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

Review 5.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

6.  Feline Immunodeficiency Virus Vif N-Terminal Residues Selectively Counteract Feline APOBEC3s.

Authors:  Qinyong Gu; Zeli Zhang; Lucía Cano Ortiz; Ana Cláudia Franco; Dieter Häussinger; Carsten Münk
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

7.  N-terminal hemagglutinin tag renders lysine-deficient APOBEC3G resistant to HIV-1 Vif-induced degradation by reduced polyubiquitination.

Authors:  Yudi Wang; Qiujia Shao; Xianghui Yu; Wei Kong; James E K Hildreth; Bindong Liu
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

8.  Hydrodynamic and functional analysis of HIV-1 Vif oligomerization.

Authors:  Stephen M Techtmann; Rodolfo Ghirlando; Sandra Kao; Klaus Strebel; Ernest L Maynard
Journal:  Biochemistry       Date:  2012-03-05       Impact factor: 3.162

9.  CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G.

Authors:  Eri Miyagi; Sandra Kao; Venkat Yedavalli; Klaus Strebel
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

10.  Core-binding factor β increases the affinity between human Cullin 5 and HIV-1 Vif within an E3 ligase complex.

Authors:  Jason D Salter; Geoffrey M Lippa; Ivan A Belashov; Joseph E Wedekind
Journal:  Biochemistry       Date:  2012-10-25       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.